Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.83 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.83 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.83 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
| ▸ | SLC18A2 | Q05940 | 9/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22186209 | 1.00 | HTR1A (0.83) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| SCHEMBL20411762 | 1.00 | HTR1A (0.83) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL19024486 | 0.91 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL872246 | 0.91 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL871303 | 0.91 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL23771726 | 0.91 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL17565511 | 0.91 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL15932979 | 0.91 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL23119371 | 0.91 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL871304 | 0.91 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169087-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS INC (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169087-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | SLC18A2, SLC6A2, SLC18A1 | HTR1A 146/4885TBXA2R 720/4885PTGS1 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.